No empirical evidence supports the link.

13. Please identify how the current state of patent eligibility jurisprudence in the United States affects the public. For example, does the jurisprudence affect, either positively or negatively, the availability, effectiveness, or cost of personalized medicine, diagnostics, pharmaceutical treatments, software, or computer-implemented inventions?

In general, restoring patent eligibility to its gatekeeper role is likely to benefit U.S. consumers by encouraging investment in innovation in fields of endeavor that have been negatively impacted by the uncertainty and unpredictability of current eligibility jurisprudence.

We are not aware of any empirical data that addresses whether the restoration of traditional section 101 eligibility—that is, providing a more certain and predictable test for patent eligibility while enabling other sections of the patent statute to perform their roles in assessing patentability—would increase or decrease consumer prices. For example, it may be just as plausible that advances might reduce costs/prices incurred by consumers in seeking products or services in that field. Various examples of the potential for reduced costs/prices are not difficult to contemplate.